Abstract
BACKGROUND: The evidence base of tisagenlecleucel is uncertain. OBJECTIVE: To evaluate the cost-effectiveness of tisagenlecleucel. To conduct expected value of perfect information (EVPI) and partial EVPI (EVPPI) analyses. STUDY DESIGN: A three-state partitioned survival model. A short-term decision tree partitioned patients in the tisagenlecleucel arm according to infusion status. Survival was extrapolated to 5 years; general population mortality with a standardised mortality ratio was then applied. EVPI and EVPPI were scaled up to population according to the incidence of the decision. SETTING: Irish healthcare payer. PARTICIPANTS: Patients with relapsed/refractory diffuse large B-cell lymphoma (R/R DLBCL). INTERVENTIONS: Tisagenlecleucel versus Salvage Chemotherapy (with or without haematopoietic stem cell transplant). MAIN OUTCOME MEASURE: Incremental cost-effectiveness ratio (ICER). Population EVPI and EVPPI. RESULTS: At list prices, the ICER was €119,509 per quality-adjusted life year (QALY) (incremental costs €218,092; incremental QALYs 1.82). Probability of cost-effectiveness, at a €45,000 per QALY threshold, was 0%. Population EVPI was €0.00. Population EVPI, at the price of tisagenlecleucel that reduced the ICER to €45,000 per QALY, was €3,989,438. Here, survival analysis had the highest population EVPPI (€1,128,053). CONCLUSION: Tisagenlecleucel is not cost-effective, versus salvage chemotherapy (with or without haematopoietic stem cell transplant), for R/R DLBCL in Ireland. At list prices, further research to decrease decision uncertainty may not be of value.